Abbott Laboratories Stock Price, Forecast & Analysis (NYSE:ABT)

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Thursday, September 12th. Shareholders of record on Tuesday, October 15th will be paid a dividend of $0.32 per share on Friday, November 15th. This represents a $1.28 dividend on an annualized basis and a yield of 1.52%. The ex-dividend date is Friday, October 11th. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, October, 16th. The healthcare product maker reported $0.84 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.84. The healthcare product maker earned $8.08 billion during the quarter, compared to the consensus estimate of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. The company's quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business earned $0.75 EPS. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 22nd 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories updated its FY19 earnings guidance on Wednesday, October, 16th. The company provided earnings per share guidance of $3.23-3.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.24.

17 Wall Street analysts have issued 12 month price targets for Abbott Laboratories' stock. Their forecasts range from $68.00 to $98.00. On average, they expect Abbott Laboratories' share price to reach $87.22 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Press coverage about ABT stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the healthcare product maker a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Abbott Laboratories.

Abbott Laboratories saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 16,670,000 shares, a decline of 5.8% from the September 30th total of 17,690,000 shares. Based on an average daily trading volume, of 4,520,000 shares, the short-interest ratio is currently 3.7 days. Approximately 1.0% of the shares of the company are sold short. View Abbott Laboratories' Current Options Chain.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Micron Technology (MU), Pfizer (PFE), Walt Disney (DIS), CA (CA), Intel (INTC) and NVIDIA (NVDA).

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (1.80%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), Diamond Hill Capital Management Inc. (0.36%), California Public Employees Retirement System (0.23%), Rhumbline Advisers (0.19%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Coho Partners Ltd., Massachusetts Financial Services Co. MA, Columbus Circle Investors, Sawgrass Asset Management LLC, Montag & Caldwell LLC, Sector Gamma AS, State of New Jersey Common Pension Fund D and BB&T Securities LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, Assenagon Asset Management S.A., State of Tennessee Treasury Department, Bartlett & Co. LLC, State of Alaska Department of Revenue, Banco Santander S.A. and First Trust Advisors LP. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $84.12.

Abbott Laboratories has a market capitalization of $148.76 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.